On 24 February 2026, Episurf Medical AB (publ) ("Episurf") issued convertibles in an aggregated nominal amount of SEK 87,380,906 as part of the consideration to be paid for the acquisition of Frusipe Intressenter Target 1 AB. Convertibles in a nominal amount of SEK 37,519,480 have, as of the date of this press release, at the request from holders of convertibles, been converted into 833,766,222 Class B shares in Episurf at a conversion price of SEK 0.045 per share in accordance with the terms and conditions.
Through the conversion, the number of Class B shares and votes in Episurf increases by 833,766,222, corresponding to a dilution effect of approximately 12.03 per cent of the shares and the votes respectively. Through the conversion, the share capital increases by SEK 8,337,662.22.
For further details, please contact:
Jens Andersson, CEO, Episurf Medical
Tel: +46 (0) 768 55 67 02
Email: jens.andersson@episurf.com
The information was submitted for publication, through the agency of the contact person set out above, at 19:30 CEST on 22 June, 2026.
About Episurf Medical AB
Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The company's objective is to create value growth through the acquisition and management of Nordic properties. The company also has a medical technology business based on the individualised implant Episealer® and associated surgical instruments, which are used to treat cartilage injuries in joints. Episurf Medical's head office is located in Stockholm, Sweden.